Program
enlonstobart
Also written as “SG001”, “Enlonstobart” and “SYS6041, enlonstobart, bevacizumab”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Esophageal Squamous Cell Carcinoma · Stomach Neoplasms · Uterine Cervical Neoplasms · Ovarian Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSPC Pharmaceutical Group | 1410 open or running | phase 3since Jan 16, 2023 | Feb 20, 2019 | Apr 2027phase 2 · NCT06136988 |
| Shanghai Runshi Pharmaceutical Technology | 11 open or running | phase 2since Nov 9, 2023 | Nov 9, 2023 | Jan 30, 2027phase 2 · NCT06132217 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Feb 20, 2019.
- Apr 26, 2021Phase 2 study in Uterine Cervical NeoplasmsCSPC Pharmaceutical Group · NCT04886700 · 104 enrolled · China
- Jul 16, 2021Phase 2 study in Carcinoma, Ovarian EpithelialCSPC Pharmaceutical Group · NCT04983550 · 126 enrolled
- Sep 9, 2021Phase 2 study in Triple Negative Breast NeoplasmsCSPC Pharmaceutical Group · NCT05068141 · 79 enrolled · China
- Jan 16, 2023Phase 3 study in RecurrenceCSPC Pharmaceutical Group · NCT05715840 · 368 planned
- Oct 13, 2023Phase 2 study in Colorectal NeoplasmsCSPC Pharmaceutical Group · NCT06089330 · 102 planned
- Nov 8, 2023Phase 2 study in Locally Advanced Unresectable Esophageal Squamous CarcinomaCSPC Pharmaceutical Group · NCT06136988 · 129 planned · China
- Nov 9, 2023Shanghai Runshi Pharmaceutical Technology's first study: phase 2 study in Advanced Solid TumorNew to Shanghai Runshi Pharmaceutical TechnologyShanghai Runshi Pharmaceutical Technology · NCT06132217 · 168 planned · China
- May 12, 2025Phase 2 study in HER2-positive Gastric CancerCSPC Pharmaceutical Group · NCT06998771 · 153 planned
- Nov 13, 2025Phase 3 study in Esophageal Squamous Cell CarcinomaCSPC Pharmaceutical Group · NCT07251062 · 737 planned
- Dec 25, 2025Phase 3 study in HER2-positive Gastric CancerCSPC Pharmaceutical Group · NCT07332533 · 490 planned
- May 31, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungCSPC Pharmaceutical Group · NCT07633873 · 500 planned
- Jun 21, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungCSPC Pharmaceutical Group · NCT07672223 · 586 planned · China
- Jul 8, 2026Phase 2 study in Ovarian NeoplasmsCSPC Pharmaceutical Group · NCT07714668 · 171 planned · China
- Oct 26, 2026Phase 3 study in Esophageal Squamous Cell CarcinomaCSPC Pharmaceutical Group · NCT07924111 · 585 planned
Ahead
- Jan 30, 2027Primary completion: phase 2 study in Advanced Solid TumorShanghai Runshi Pharmaceutical Technology · NCT06132217
- Apr 2027Primary completion: phase 2 study in Locally Advanced Unresectable Esophageal Squamous CarcinomaCSPC Pharmaceutical Group · NCT06136988
- Sep 30, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungCSPC Pharmaceutical Group · NCT07633873
- Apr 30, 2028Primary completion: phase 2 study in Ovarian NeoplasmsCSPC Pharmaceutical Group · NCT07714668
TargetBeta
“A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
| sasanlimab | Pfizer | phase 3 | 4 |
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07924111Esophageal Squamous Cell Carcinoma | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Dec 30, 2029 | 585 |
| NCT07714668Ovarian Neoplasms · China | 2 | Recruiting | CSPC Pharmaceutical Group | Apr 30, 2028 | 171 |
| NCT07672223Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | CSPC Pharmaceutical Group | Sep 30, 2029 | 586 |
| NCT07633873Carcinoma, Non-Small-Cell Lung | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Sep 30, 2027 | 500 |
| NCT07332533HER2-positive Gastric Cancer | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Jun 30, 2032 | 490 |
| NCT07251062Esophageal Squamous Cell Carcinoma | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Dec 30, 2029 | 737 |
| NCT06998771HER2-positive Gastric Cancer | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Jun 30, 2028 | 153 |
| NCT06132217Advanced Solid Tumor · China | 2 | Not yet recruiting | Shanghai Runshi Pharmaceutical Technology | Jan 30, 2027 | 168 |
| NCT06136988Locally Advanced Unresectable Esophageal Squamous Carcinoma · China | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Apr 2027 | 129 |
| NCT06089330Colorectal Neoplasms | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Jul 2024 | 102 |
| NCT05715840Recurrence | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Jul 31, 2024 | 368 |
| NCT05068141Triple Negative Breast Neoplasms · China | 2 | UNKNOWN | CSPC Pharmaceutical Group | Oct 1, 2022 | 79 |
| NCT04983550Carcinoma, Ovarian Epithelial | 2 | UNKNOWN | CSPC Pharmaceutical Group | Jan 2023 | 126 |
| NCT04886700Uterine Cervical Neoplasms · China | 2 | UNKNOWN | CSPC Pharmaceutical Group | Dec 31, 2022 | 104 |
| NCT03852823Uterine Cervical Neoplasms · China | 1 | UNKNOWN | CSPC Pharmaceutical Group | Sep 2022 | 192 |
How it is read
Names in the registry
- “SG001”, 8 entries
- “Enlonstobart”, 3 entries
- “SYS6041, enlonstobart, bevacizumab”, 1 entry
- “Enlonstobart injection”, 1 entry
- “SYS6010+SG001+ physician's choice (Capecitabine or 5-FU)”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Esophageal Squamous Cell Carcinoma, 2 studies
- Stomach Neoplasms, 2 studies
- Uterine Cervical Neoplasms, 2 studies
- Ovarian Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.